Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma

BMC Gastroenterology

Claudio Tiribelli³  Lory S Crocè³  Paola Francalanci²  Giuliano Torre²  Beatrice Anfuso¹  Devis Pascut¹  Natalia Rosso¹  Caecilia HC Sukowati¹ 

[1] Centro Studi Fegato, Fondazione Italiana Fegato, Bld Q AREA Science Park Basovizza, Trieste, Italy;Ospedale Pediatrico Bambino Gesù, Rome, 00100, Italy;Department of Medicine, University of Trieste, Trieste, 34100, Italy

关键词: Doxorubicin;    Gene expression;    Drug resistance;    Liver cancer;   

Others  :  858303
DOI  :  10.1186/1471-230X-12-160

 received in 2012-07-23, accepted in 2012-11-01,  发布年份 2012

【 摘 要 】

Background

The Breast Cancer Resistance Protein (BCRP/ABCG2) is one member of ABC transporters proteins super family responsible of drug resistance. Since data on ABCG2 expression in liver malignances are scanty, here we report the expression of ABCG2 in adult human hepatocellular carcinoma (HCC) in both in vivo and in vitro models with different degree of malignancy.

Methods

In cell lines derived from human hepatocellular carcinoma, ABCG2 gene expression was assessed by reverse transcription quantitative real time PCR and function by Hoechst 33342 efflux assay; protein content was assessed by SDS-PAGE Western blot.

Results

ABCG2 expression was found to be highest in the most undifferentiated cell lines, and this was related with a higher functional activity. ABCG2 expression was sensitive to antineoplastic drugs since exposure to 5 μM doxorubicin for 24 hours resulted in significant up-regulations of ABCG2 in all cell lines, particularly in those lines with low basal ABCG2 expression (p<0.01). The gene expression was also investigated in 51 adult liver tissues with HCC and related cirrhosis; normal liver tissue was used as control. ABCG2 gene expression was higher in HCC than both cirrhotic paired tissue and normal tissue. This up-regulation was greater (p<0.05) in pathological poorly differentiated grade G3/G4 than in well-differentiated G1/G2 HCC.

Conclusions

Our results suggest a correlation of ABCG2 gene expression and differentiation stage both in human and HCC derived cell lines. The rapid up-regulation of ABCG2 to exposure to doxorubicin emphasizes the importance of this transporter in accounting for drug resistance in liver tumors.

【 授权许可】

   
2012 Sukowati et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
• [2]Villanueva A, Llovet JM: Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011, 140:1410-1426.
• [3]Dean M, Hamon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001, 42:1007-1017.
• [4]Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001, 61:3458-3464.
• [5]Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K, Bates SE: Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett 2006, 235:84-92.
• [6]Diestra JE, Scheffer GL, Catala I, Maliepaard M, Schellens JH, Scheper RJ, Germa-Lluch JR, Izquierdo MA: Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002, 198:213-219.
• [7]Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000, 113(Pt 11):2011-2021.
• [8]Burger H, Nooter K: Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle 2004, 3:1502-1505.
• [9]Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD: Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 2006, 98:1739-1742.
• [10]Sun Z, Zhao Z, Li G, Dong S, Huang Z, Ye L, Liang H, Qu J, Ai X, Zhang W, Chen X: Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies. Tumori 2010, 96:90-96.
• [11]Kamiyama N, Takagi S, Yamamoto C, Kudo T, Nakagawa T, Takahashi M, Nakanishi K, Takahashi H, Todo S, Iseki K: Expression of ABC transporters in human hepatocyte carcinoma cells with cross-resistance to epirubicin and mitoxantrone. Anticancer Res 2006, 26:885-888.
• [12]Barnes SN, Aleksunes LM, Augustine L, Scheffer GL, Goedken MJ, Jakowski AB, Pruimboom-Brees IM, Cherrington NJ, Manautou JE: Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug Metab Dispos 2007, 35:1963-1969.
• [13]Vander Borgth S, van Pelt J, van Malenstein H, Cassiman D, Renard M, Verslype C, Libbrecht L, Roskams TA: Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and in vitro. Hepatol Res 2008, 38:1112-1121.
• [14]Jin Y, Bin ZQ, Qiang H, Liang C, Hua C, Jun D, Dong WA, Qing L: ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol 2009, 135:1369-1376.
• [15]Hu C, Li H, Li J, Zhu Z, Yin S, Hao X, Yao M, Zheng S, Gu J: Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 2008, 29:2289-2297.
• [16]Shi GM, Xu Y, Fan J, Zhou J, Yang XR, Qiu SJ, Liao Y, Wu WZ, Ji Y, Ke AW, Ding ZB, He YZ, Wu B, Yang GH, Qin WZ, Zhang W, Zhu J, Min ZH, Wu ZQ: Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 2008, 134:1155-1163.
• [17]Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001, 7:1028-1034.
• [18]Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP: Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 2002, 99:12339-12344.
• [19]Shimano K, Satake M, Okaya A, Kitanaka J, Kitanaka N, Takemura M, Sakagami M, Terada N, Tsujimura T: Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1. Am J Pathol 2003, 163:3-9.
• [20]Zen Y, Fujii T, Yoshikawa S, Takamura H, Tani T, Ohta T, Nakanuma Y: Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am J Pathol 2007, 170:1750-1762.
• [21]Schippers IJ, Moshage H, Roelofsen H, Muller M, Heymans HS, Ruiters M, Kuipers F: Immortalized human hepatocytes as a tool for the study of hepatocytic (de-)differentiation. Cell Biol Toxicol 1997, 13:375-386.
• [22]Edmondson HA, STEINER PE: Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954, 7:462-503.
• [23]Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
• [24]Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622.
• [25]Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
• [26]Schmittgen TD, Zakrajsek BA: Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 2000, 46:69-81.
• [27]Plumb JA, Milroy R, Kaye SB: The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem Pharmacol 1990, 39:787-792.
• [28]Blum HE: Molecular targets for prevention of hepatocellular carcinoma. Dig Dis 2002, 20:81-90.
• [29]Li G, Chen X, Wang Q, Xu Z, Zhang W, Ye L: The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance. J Huazhong Univ Sci Technolog Med Sci 2007, 27:173-175.
• [30]Zhang Y, Gupta A, Wang H, Zhou L, Vethanayagam RR, Unadkat JD, Mao Q: BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 2005, 22:2023-2034.
• [31]Ross DD, Karp JE, Chen TT, Doyle LA: Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000, 96:365-368.
• [32]Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G, Nooter K: RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003, 9:827-836.
• [33]Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, Yamada Y, Kamihira S, Kohno S: Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res 2003, 9:3052-3057.
• [34]Gupta N, Martin PM, Miyauchi S, Ananth S, Herdman AV, Martindale RG, Podolsky R, Ganapathy V: Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. Biochem Biophys Res Commun 2006, 343:571-577.
• [35]Apati A, Orban TI, Varga N, Nemeth A, Schamberger A, Krizsik V, Erdelyi-Belle B, Homolya L, Varady G, Padanyi R, Karaszi E, Kemna EW, Nemet K, Sarkadi B: High level functional expression of the ABCG2 multidrug transporter in undifferentiated human embryonic stem cells. Biochim Biophys Acta 2008, 1778:2700-2709.
• [36]Scharenberg CW, Harkey MA, Torok-Storb B: The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002, 99:507-512.
• [37]Chen Z, Liu F, Ren Q, Zhao Q, Ren H, Lu S, Zhang L, Han Z: Suppression of ABCG2 inhibits cancer cell proliferation. Int J Cancer 2010, 126:841-851.